TELA Bio (TELA)
(Delayed Data from NSDQ)
$2.54 USD
+0.05 (2.01%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $2.56 +0.02 (0.79%) 5:18 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.54 USD
+0.05 (2.01%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $2.56 +0.02 (0.79%) 5:18 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Zacks News
Zai Lab Limited (ZLAB) Surges 11.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
TELA Bio (TELA) delivered earnings and revenue surprises of -13.33% and 15.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Artivion (AORT) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 133.33% and 0.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 16.10% and 5.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The Joint Corp. (JYNT) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
The Joint (JYNT) delivered earnings and revenue surprises of 300% and 1.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Syros Pharmaceuticals (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TELA Bio (TELA) delivered earnings and revenue surprises of -20.45% and 2.09%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 8.62% and 174.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 23.26% and 45.42%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Surges 10.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of 20.69% and 0.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 15.38% and 21.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Roivant Sciences Ltd. (ROIV) Surges 8.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Roivant Sciences Ltd. (ROIV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Strength Seen in TELA Bio, Inc. (TELA): Can Its 11.4% Jump Turn into More Strength?
by Zacks Equity Research
TELA Bio, Inc. (TELA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
TELA Bio, Inc. (TELA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -23.53% and 2.39%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
SmileDirectClub (SDC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
SmileDirectClub (SDC) delivered earnings and revenue surprises of -14.29% and 9.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of 10.34% and 12.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 3.12% and 3.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. (TELA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -12.28% and 4.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -146.67% and 121.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Biogen Inc. (BIIB) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.50% and 1.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. (TELA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -33.33% and 1.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 3.30% and 2.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 290.91% and 73.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
uniQure (QURE) Moves 27% Higher: Will This Strength Last?
by Zacks Equity Research
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.